Dapasmart: Advanced Relief for Neuropathic Pain
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $5.10 | $71.44 (0%) | 🛒 Add to cart |
| 28 | $4.28 | $142.89 $119.74 (16%) | 🛒 Add to cart |
| 56 | $3.92 | $285.77 $219.36 (23%) | 🛒 Add to cart |
| 84 | $3.76 | $428.66 $315.96 (26%) | 🛒 Add to cart |
| 112 | $3.54 | $571.55 $396.46 (31%) | 🛒 Add to cart |
| 168 | $3.44
Best per pill | $857.32 $578.59 (33%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.82 | $67.42 (0%) | 🛒 Add to cart |
| 28 | $3.92 | $134.84 $109.68 (19%) | 🛒 Add to cart |
| 56 | $3.59 | $269.67 $201.25 (25%) | 🛒 Add to cart |
| 84 | $3.52 | $404.51 $295.84 (27%) | 🛒 Add to cart |
| 112 | $3.41 | $539.35 $382.37 (29%) | 🛒 Add to cart |
| 168 | $3.25
Best per pill | $809.02 $545.38 (33%) | 🛒 Add to cart |
Synonyms | |||
Dapasmart represents a significant advancement in the management of neuropathic pain, offering a targeted therapeutic approach for patients who have found limited success with conventional analgesics. Formulated with Pregabalin, a well-established and potent neuromodulator, this medication is designed to specifically calm hyperexcited nerves, providing substantial relief from the burning, shooting, and tingling sensations characteristic of nerve damage. By addressing the root cause of neuropathic discomfort rather than merely masking symptoms, Dapasmart empowers patients to reclaim a higher quality of life, facilitating improved sleep, daily function, and overall well-being under professional medical guidance.
Features
- Active Ingredient: Pregabalin
- Standard Dosage Strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
- Formulation: Film-coated tablets for oral administration
- Pharmacokinetics: Rapid absorption with peak plasma concentrations achieved within 1.5 hours; bioavailability is ≥90% and independent of food intake
- Mechanism of Action: Binds potently to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of several excitatory neurotransmitters
- Half-life: Approximately 6.3 hours in patients with normal renal function
- Primary Excretion: Renal excretion of unchanged drug; dosage adjustment required in renal impairment
- Manufacturing Standards: Produced in cGMP-certified facilities ensuring batch-to-batch consistency and purity
Benefits
- Provides significant reduction in neuropathic pain scores, as demonstrated in multiple randomized controlled trials, leading to improved patient-reported outcomes.
- Enhances sleep quality by alleviating pain that often disrupts sleep architecture, allowing for more restorative rest.
- Reduces the overall burden of chronic pain, thereby decreasing the reliance on rescue medications like opioids and their associated risks.
- Improves functional capacity and daily activities, enabling patients to engage more fully in work, social, and physical rehabilitation.
- Offers a predictable pharmacokinetic profile with a low potential for pharmacokinetic drug interactions, simplifying polypharmacy management.
- Supports long-term pain management strategies with a well-documented efficacy and safety profile established over years of clinical use.
Common use
Dapasmart (Pregabalin) is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. It is also extensively used off-label for other neuropathic pain conditions, including central neuropathic pain (e.g., following spinal cord injury), fibromyalgia, and as an adjunct therapy for partial-onset seizures in adults. Its use is predicated on a confirmed diagnosis of neuropathic pain by a healthcare professional, typically after first-line treatments such as tricyclic antidepressants or serotonin-norepinephrine reuptake inhibitors have provided insufficient relief or were not tolerated. Treatment is usually initiated at a low dose and titrated gradually based on therapeutic response and tolerability, forming a core component of a multidisciplinary pain management plan that may include physical therapy and psychological support.
Dosage and direction
The dosage of Dapasmart must be individualized according to the patient’s renal function and therapeutic response. For neuropathic pain, the recommended starting dose is 150 mg per day, administered orally in two or three divided doses (e.g., 75 mg twice daily or 50 mg three times daily). Based on efficacy and tolerability, the dose may be increased to 300 mg per day within one week. If needed, and if tolerated, the dose can be further increased to a maximum of 600 mg per day in divided doses after an additional week. For patients with renal impairment, dosage reduction is mandatory; refer to creatinine clearance (CrCl) guidelines: CrCl 30-60 mL/min: max 300 mg/day; CrCl 15-30 mL/min: max 150 mg/day; CrCl <15 mL/min: max 75 mg/day. Administration can occur with or without food. Tablets should be swallowed whole with water and not crushed, chewed, or split. Abrupt discontinuation should be avoided; taper gradually over a minimum of one week to minimize potential withdrawal symptoms.
Precautions
Patients should be cautioned about the potential for dizziness, somnolence, and blurred vision, which could impair their ability to perform hazardous tasks such as driving or operating machinery, especially during the initial titration phase. There is a risk of angioedema, presenting as swelling of the face, mouth, or throat; patients should seek immediate medical attention if these symptoms occur. Use with caution in patients with a history of heart failure due to potential fluid retention and weight gain. Regular monitoring of weight and symptoms of edema is advised. Pregabalin has been associated with euphoria and potential for abuse, particularly in patients with a history of substance use disorder; careful supervision is required. Ophthalmological examinations are recommended for patients reporting visual disturbances. Patients should avoid alcohol consumption as it may potentiate CNS depressant effects.
Contraindications
Dapasmart is contraindicated in patients with known hypersensitivity to Pregabalin or any of the excipients in the formulation. Its use is also contraindicated in combination with thiazolidinedione antidiabetic agents (e.g., pioglitazone) due to an increased risk of weight gain and fluid retention, which may exacerbate or lead to heart failure. It should not be used in patients with severe renal impairment (CrCl <15 mL/min) unless on dialysis, and even then, with extreme caution and significant dose adjustment.
Possible side effect
The most commonly reported adverse reactions (occurring in ≥5% of patients and twice the rate of placebo) include dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and disturbances in attention/thinking. Less common but serious side effects can include angioedema, hypersensitivity reactions (e.g., skin rash, pruritus), suicidal ideation and behavior, rhabdomyolysis, and thrombocytopenia. Many side effects are dose-dependent and may diminish with continued therapy or dose reduction. Patients should be instructed to report any persistent or severe adverse effects to their healthcare provider promptly.
Drug interaction
Dapasmart has a low potential for pharmacokinetic interactions as it is not metabolized by the liver’s cytochrome P450 enzyme system and is excreted renally unchanged. However, pharmacodynamic interactions are significant. Concomitant use with other central nervous system depressants (e.g., opioids, benzodiazepines, barbiturates, alcohol) can potentiate sedation, respiratory depression, dizziness, and cognitive impairment. Coadministration with thiazolidinediones (as noted in Contraindications) is not recommended. Caution is advised when used with ACE inhibitors due to a potential increased risk of angioedema. It may enhance the fluid-retaining effects of other drugs. No clinically significant interactions have been found with oral contraceptives, glyburide, insulin, or digoxin.
Missed dose
If a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should be advised not to double the next dose to make up for a missed one, as this increases the risk of adverse effects. Maintaining a consistent daily schedule is important for stable pain control.
Overdose
In cases of acute overdose, signs and symptoms are primarily related to an exaggeration of its pharmacological effects, including severe somnolence, lethargy, restlessness, agitation, confusion, depression, and seizures. There is no specific antidote for Pregabalin overdose. Management involves general supportive measures and symptomatic treatment. Gastric lavage may be considered if performed soon after ingestion. Hemodialysis can significantly remove Pregabalin from the plasma (approximately 50% over 4 hours) and should be considered in cases of severe overdose, especially in patients with renal compromise. Vital signs and consciousness level should be monitored closely, and respiratory support instituted if necessary.
Storage
Store Dapasmart tablets at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original blister pack or bottle to protect it from light and moisture. Keep the container tightly closed and out of the reach of children and pets. Do not store in bathrooms or other areas with high humidity. Properly discard any expired or unused medication via a medicine take-back program or according to local guidelines; do not flush down the toilet or pour into a drain.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this product description. The efficacy and safety profile described are based on clinical data for the active ingredient, Pregabalin; individual patient experiences may vary.
Reviews
“After years of struggling with diabetic neuropathy pain that limited my mobility and sleep, my neurologist prescribed Dapasmart. The titration was gradual, but within a month, the constant burning in my feet had reduced by about 70%. I am finally able to sleep through the night and take walks again. The dizziness was noticeable at first but subsided.” — Martha R., 68, diagnosed with Diabetic Peripheral Neuropathy
“As a pain specialist, I have incorporated Pregabalin (Dapasmart) into my treatment protocols for over a decade. Its predictable efficacy and favorable interaction profile make it a cornerstone for neuropathic pain management. I find it particularly valuable for patients with postherpetic neuralgia who have not responded adequately to gabapentin. Monitoring for edema and weight gain is essential, but for most, the benefits far outweigh the risks.” — Dr. Evan Sterling, MD, Neurology
“I was initially skeptical about adding another medication, but the post-surgical nerve pain from my spinal injury was debilitating. Dapasmart provided relief that opioids never could, without the foggy feeling. It gave me the clarity to focus on my physical therapy. The only downside has been some weight gain, which we are managing with diet.” — James K., 45, status post Spinal Fusion Surgery
“The consistency of the 150 mg tablets has been excellent for my patients with renal impairment who require precise dosing. It integrates well into complex regimens. It’s a reliable and well-manufactured product in my clinical experience.” — Dr. Lena Mireles, PharmD, Clinical Pharmacist
“I’ve tried numerous medications for my fibromyalgia. Dapasmart, combined with gentle exercise, has been the most effective at reducing the widespread pain and ‘brain fog.’ It took some time to find the right dose, but the improvement in my quality of life has been profound.” — Sarah T., 52, diagnosed with Fibromyalgia